August 20, 2020 -- IsoPlexis and Lonza have partnered to advance automated cell therapy manufacturing.
The partnership will utilize IsoPlexis' IsoLight automated cell manufacturing platform and Lonza's Cocoon automated cell therapy manufacturing solution to perform end-to-end automation. Notably, IsoLight will perform functional proteomics analysis on cell therapy products created by Cocoon.
IsoLight provides functional characterization of cell therapy products for correlative functional potency, according to IsoPlexis. Meanwhile, Cocoon enables centralized and decentralized manufacturing of novel cell therapies, noted Lonza.